[{"address1": "700 Quince Orchard Road", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 268 2000", "website": "https://www.novavax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 1543, "companyOfficers": [{"maxAge": 1, "name": "Mr. John Charles Jacobs M.B.A.", "age": 56, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1329651, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Joseph Trizzino B.S., M.B.A.", "age": 63, "title": "President & COO", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 670550, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James Patrick Kelly C.F.A.", "age": 57, "title": "Executive VP, CFO & Treasurer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 716175, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Casey", "age": 60, "title": "Executive VP, Chief Legal Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 137357, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stanley Charles Erck", "age": 75, "title": "Advisor", "yearBorn": 1948, "fiscalYear": 2023, "totalPay": 1408007, "exercisedValue": 0, "unexercisedValue": 487116}, {"maxAge": 1, "name": "Dr. Filip  Dubovsky FAAP, M.D., M.P.H.", "age": 58, "title": "President of Research & Development", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 858768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard P. Crowley", "age": 66, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Troy  Morgan Esq., J.D.", "age": 52, "title": "Senior VP & Chief Compliance Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erika S. Trahan", "title": "Associate Director of Investor & Public Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ian J. Watkins", "age": 60, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 4, "compensationRisk": 5, "shareHolderRightsRisk": 5, "overallRisk": 5, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.novavax.com/go.cfm?do=Stock.GetQuote", "maxAge": 86400, "priceHint": 2, "previousClose": 15.7, "open": 16.16, "dayLow": 14.84, "dayHigh": 16.21, "regularMarketPreviousClose": 15.7, "regularMarketOpen": 16.16, "regularMarketDayLow": 14.84, "regularMarketDayHigh": 16.21, "beta": 1.62, "forwardPE": -15.30303, "volume": 17670599, "regularMarketVolume": 17670599, "averageVolume": 12952250, "averageVolume10days": 49546700, "averageDailyVolume10Day": 49546700, "bid": 15.09, "ask": 15.17, "bidSize": 4900, "askSize": 6600, "marketCap": 2231564544, "fiftyTwoWeekLow": 3.53, "fiftyTwoWeekHigh": 17.4, "priceToSalesTrailing12Months": 2.2391574, "fiftyDayAverage": 6.318, "twoHundredDayAverage": 6.1026, "currency": "USD", "enterpriseValue": 2227581952, "profitMargins": -0.40006, "floatShares": 124179923, "sharesOutstanding": 147298000, "sharesShort": 44934930, "sharesShortPriorMonth": 43907229, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.32, "heldPercentInsiders": 0.04971, "heldPercentInstitutions": 0.5745, "shortRatio": 12.31, "shortPercentOfFloat": 0.4136, "impliedSharesOutstanding": 147298000, "bookValue": -6.177, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -398707008, "trailingEps": -3.05, "forwardEps": -0.99, "pegRatio": 3.03, "lastSplitFactor": "1:20", "lastSplitDate": 1557446400, "enterpriseToRevenue": 2.235, "enterpriseToEbitda": -6.673, "52WeekChange": 1.1012483, "SandP52WeekChange": 0.25262225, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "NVAX", "underlyingSymbol": "NVAX", "shortName": "Novavax, Inc.", "longName": "Novavax, Inc.", "firstTradeDateEpochUtc": 818173800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cdb3cddb-5091-3918-86d6-9b4894e61c6c", "messageBoardId": "finmb_350381", "gmtOffSetMilliseconds": -14400000, "currentPrice": 15.15, "targetHighPrice": 38.0, "targetLowPrice": 10.0, "targetMeanPrice": 18.0, "targetMedianPrice": 12.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 480585984, "totalCashPerShare": 3.423, "ebitda": -333844992, "totalDebt": 581054016, "quickRatio": 0.624, "currentRatio": 0.904, "totalRevenue": 996609024, "revenuePerShare": 8.726, "returnOnAssets": -0.16322, "freeCashflow": -1195161600, "operatingCashflow": -471928992, "revenueGrowth": 0.159, "grossMargins": 0.049200002, "ebitdaMargins": -0.33498, "operatingMargins": -1.47814, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-24"}]